Compare IQV & CLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | CLS |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | Canada |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 41.9B |
| IPO Year | 2013 | 1999 |
| Metric | IQV | CLS |
|---|---|---|
| Price | $273.59 | $250.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | $302.67 | ★ $471.14 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 10-27-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.67 | ★ 98.34 |
| EPS | 1.61 | ★ 5.01 |
| Revenue | $9,739,000,000.00 | ★ $12,390,900,000.00 |
| Revenue This Year | $6.79 | $66.31 |
| Revenue Next Year | $6.06 | $73.28 |
| P/E Ratio | $172.91 | ★ $51.82 |
| Revenue Growth | ★ 41.60 | 28.46 |
| 52 Week Low | $154.50 | $249.02 |
| 52 Week High | $282.98 | $474.03 |
| Indicator | IQV | CLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 28.16 |
| Support Level | $252.55 | N/A |
| Resistance Level | $274.49 | $316.65 |
| Average True Range (ATR) | 7.84 | 19.68 |
| MACD | 1.06 | -10.99 |
| Stochastic Oscillator | 67.59 | 4.45 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.